Levothyroxine Sodium Market By Disease Indication (Hypothyroidism, Goiter, Thyroid Cancer, Myxedema Coma) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

Hypothyroidism as a syndrome was first recognized in the 1870s, and its treatment with animal-extracted thyroid was achieved in the 1890s. Since 1927, synthetic thyroid hormone replacement therapy has been available, and in recent years, there has been a minor shift in treatment away from levothyroxine. The use of liothyronine T3 as monotherapy or in combination with levothyroxine T3/T4 is currently a popular treatment option. The current T3/T4 formulation, however, does not completely replicate the natural hormone pattern released by the human thyroid. Therefore, levothyroxine formulations have been widely available across the global market.

Treating hypothyroidism or underactive thyroid disease remains the single largest application of levothyroxine sodium. Treatment goals include correcting catabolic imbalances and reversing clinical progressions. According to the AACE (American Association of Clinical Endocrinologists), nearly 27 million people suffer from various thyroid disorders, most suffering from hypothyroidism—autoimmune thyroiditis and iodine deficiency being the most common causes. In the coming years, an increase in demand for levothyroxine to treat thyroid cancer may drive up sales of levothyroxine sodium products.

Levothyroxine sodium, sold under the brand name Synthroid, is a thyroid hormone approved by the Food and Drug Administration. The drug is considered to be as effective as branded versions of the same medication. In addition, the American Thyroid Association (ATA) has found no better alternatives than levothyroxine sodium; therefore, its guidelines confirm that levothyroxine sodium would remain the most preferred treatment choice for hypothyroidism. In addition, the ATA's task force on thyroid replacement has recommended liothyronine combination therapy or thyroid extract therapy as an alternative to levothyroxine monotherapy, making these treatments less desirable than using levothyroxine alone.

Market Synopsis

Hypothyroidism to occupy the largest revenue share through the forecast period

Hypothyroidism is a common thyroid disorder observed worldwide. Autoimmune diseases (Hashimoto's thyroiditis) and iodine deficiency account for the vast majority of primary hypothyroidism cases. Approximately one-third of the global population is housed in iodine-deficient areas, and the consequences of iodine deficiency often manifest through growth disorders and hypothyroidism. Hypothyroidism is ten times more prevalent in women than in men, whereas the prevalence of untreated overt hypothyroidism is significantly low. However, the implementation of new thyroid function testing and low threshold treatment indications for thyroid disorders has resulted in a growth in the number of prescriptions for levothyroxine for hypothyroidism. Overt hypothyroidism was found in 0.2% to 5.3% of people in Europe and 0.3% to 3.7% of people in the United States.

Asia-Pacific is on track to become a significant market for levothyroxine sodium.

North America remains the largest market for levothyroxine sodium drugs on the global front. The American Thyroid Association reports that approximately 12% of the U.S. population will develop thyroid conditions during their lifetime, and 20 million Americans have some form of thyroid condition at any given time. The high prevalence of thyroid disorders, better diagnostic regimens, and smaller treatment thresholds are the key factors supporting the global dominance of the North American market. Additionally, better reimbursements for levothyroxine drug regimens both for short- and long-term treatments drive the market's growth. On the other hand, Asia Pacific will progress at a faster growth rate during the forecast period from 2018 to 2026. Rapidly growing awareness and significant untapped opportunities, along with an evidently large patient population, contribute to the rapid progress of the Asia-Pacific market. China and India are the most prominent markets for levothyroxine drugs. The prevalence of subclinical hypothyroidism in China has risen to 3.22%. A large cross-sectional multicity study in India reported a high prevalence of hypothyroidism (10%).

Periods of History and Forecast

This research report presents the analysis of each considered segment from 2016 to 2026, with 2017 as the base year for estimations. In addition, each segment's compounded annual growth rates (CAGRs) are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The levothyroxine sodium market report provides a quantitative assessment of the industry in terms of current and forecasted market size while also presenting the market dynamics. This market is segmented based on disease indications and geography.

In this report, the in-trend market dynamics of the global levothyroxine sodium industry are studied to reflect the qualitative and quantitative information pertaining to the industry. Factors such as drivers and challenges are studied in the report to determine the prevalent market trends. Opportunities for new and existing market players are also enumerated in this report. This study also includes profiling key market players in terms of their business overview, financial status, product offerings, and key developments. Some of the major players profiled in this report include Mylan Laboratories, Inc., Farmak (Farmak Group N.V.), Goldline Laboratories, Inc., IBSA Institut Biochimique SA, Fresenius Kabi USA Llc, Piramal Critical Care Ltd., Cediprof, Inc., King Pharmaceuticals Research And Development Llc, Abbvie, Inc., Takeda Pharmaceutical Company Ltd., Merck KGaA, Jerome, Stevens Pharmaceuticals, Inc., Pfizer, Inc., Teva Pharmaceuticals, Abbott Laboratories, Inc., Sandoz (Novartis International AG), and Lloyd, Inc.

Key questions are answered in this report.

  • What is the current and future status of the global levothyroxine sodium market in terms of market size?
  • At what CAGR will the global levothyroxine sodium market progress during the forecast period from 2018 to 2026?
  • What are the major market opportunities present in the market?
  • Which are the major drivers and restraints shaping the trends in the global levothyroxine sodium market?
  • Why is hypothyroidism the most common disease condition for levothyroxine sodium?
  • Will the rapidly progressing Asia-Pacific market challenge the prominence of North America?

Frequently Asked Questions:

The market for Levothyroxine Sodium Market is expected to reach US$ XX Mn by 2026.

The Levothyroxine Sodium Market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

IBSA Institut Biochimique SA, Fresenius Kabi USA Llc, Piramal Critical Care Ltd., Cediprof, Inc., King Pharmaceuticals Research And Development Llc, Abbvie, Inc., Takeda Pharmaceutical Company Ltd., Merck KGaA, Jerome, Stevens Pharmaceuticals, Inc., Pfizer, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Aug 2022
Category:  Pharmaceuticals
Report ID:   59442
Report Format:   PDF
Pages:   170
Rating:    4.5 (49)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support